



**HUMANITARIAN AID
PROGRAM**

IMPACT REPORT 2025

The WFH Humanitarian Aid Program **CONTINUES TO PROVIDE HOPE IN 2025**

Hello friends,

Every year, the WFH Humanitarian Aid Program builds on the success of previous years, multiplying our impact. 2025 was no exception. We once again helped change even more lives around the world.

The Program continues to support countries along their journey to sustainability in inherited bleeding disorders care. We did this in 2025 through product donations, education, training, and government lobbying assistance. This helped us realize the following in 2025:

3,819 patients
on prophylactic treatment

298 million IUs
of factor distributed

2.3 million mg
of non-factor replacement
therapy distributed

18,387 people
with inherited bleeding
disorders (PWBDs) treated

**43,951 acute bleeding
episodes** managed

2,700 surgeries
performed

A major focus of our work last year—and every year—is helping countries provide sustainable care for their communities. This is not defined as reliance on donations, but as the development of nationally funded, government-supported treatment systems for people with bleeding disorders. While humanitarian donations remain critical for providing short-term access to care, they are not a substitute for long-term, sustainable solutions. Consequently, all WFH Humanitarian Aid Program efforts work towards clearly outlining a “sustainable pathway,” showing how countries can transition from donated products to durable, nationally supported care models that ensure consistent and equitable access for all PWBDs.

Our partners believe in this goal, and they are supporting us. In 2025, Sanofi and Sobi, and Takeda all extended their partnerships. Our other partners continued to generously donate to our cause. Also, our volunteers, staff, WFH national member organizations (NMOs), hemophilia treatment centres (HTCs), healthcare professionals (HCPs), governments, donors, members of the WFH and WFH USA boards, and our global

inherited bleeding disorders community all collaborated with us daily to maximize the impact of our efforts. All of this is truly inspiring—for me, for the WFH, and for the people of our community.

On behalf of the WFH I would like to thank all our partners for their continued support.

Regards,

Assad E. Haffar, MD, MSc

WFH Medical, Humanitarian Aid & Medical Training Director

2025 OBJECTIVES MET

✓ Accomplished

Increase by 10% the number of PWBDs treated—**14% achieved**

✓ Accomplished

Train specialists from seven countries on ultrasound diagnosis and synovectomy

✓ Accomplished

Work towards securing donations of bypassing agents for treating acute bleeds in PWBDs with inhibitors

✓ In-progress

Increase by 20% the number of children on prophylaxis



WFH Humanitarian Aid Program support since 1996

7,200+

patients on prophylactic treatment

14+ million mg

of non-factor replacement therapy

460,000+

acute bleeding episodes managed

2.5+ billion IUs

of factor distributed since inception of Program in 1996

34,700+

people with inherited bleeding disorders (PWBDs) treated

15,000+

surgeries facilitated

CASE STUDY

Venezuela

FACTOR DONATED IN 2025
12.6 million IUs

NON-FACTOR REPLACEMENT
THERAPY DONATED IN 2025
68,000 mgs

PATIENTS TREATED IN 2025
283

Non-factor replacement therapy saves boy in Venezuela

A boy from Venezuela saw his quality of life transformed thanks to non-factor replacement therapy provided by the WFH Humanitarian Aid Program. After years of severe bleeding episodes and disrupted education, he began the new therapy in 2022. Almost immediately, he stopped suffering from acute bleeds. With his health stable, he was able to return to school.



Click here to read the full story or scan the QR code.

IMPACT IN ACTION

The WFH Humanitarian Aid Program works to improve the lives of people with inherited bleeding disorders (PWBDs), giving them a quality of life that previous generations would not have thought possible.

The Program operates based on three key action pillars: supporting outreach and identification, improving quality of life, and enabling sustainable care. These pillars drive our main support activities: delivering donated factor and non-factor replacement therapy, conducting training events and providing logistics support.



Supporting outreach and identification by...

- Training general HCPs on how to recognize inherited bleeding disorders
- Supporting initiatives with local organizations to find new patients
- Encouraging our partners to increase laboratory diagnosis by providing both educational and logistics support
- Providing reagents for selected laboratory tests



Improving quality of life by...

- Collaborating with physicians to provide critical factor and non-factor replacement therapy donations
- Making life-changing surgery possible through sustainable and predictable treatment donations
- Facilitating access to care for new and existing PWBDs by working with HTC and WFH NMOs
- Encouraging the collection of patient outcome data to document improvements in care



Enabling sustainable care by...

- Supporting the establishment of medical facilities so that NMOs and HTCs can provide patients with lasting care
- Demonstrating to governments the value of treating PWBDs to support advocacy initiatives using either factor or non-factor replacement therapy
- Informing and training HCPs on new classes of treatment and new treatment methods in line with the WFH Guidelines for the Management of Hemophilia, 3rd edition



DELIVERING CARE



ADVOCATING FOR CARE



MAKING SUSTAINABLE CARE POSSIBLE

WFH support allows young Sri Lankan to walk again

CASE STUDY

Sri Lanka

FACTOR DONATED IN 2025
9.8 million IUs

NON-FACTOR REPLACEMENT
THERAPY DONATED IN 2025
119,000 mgs

PATIENTS TREATED IN 2025
269

A man from a remote Sri Lankan village, long plagued by a swollen knee and up to 30 bleeding episodes a year, was diagnosed with hemophilia A with inhibitors in 2015. After older treatments failed and a pseudotumor was found in 2020, donated products from the WFH Humanitarian Aid Program helped stabilize his condition. He underwent a successful above-knee amputation in 2022, later received a prosthetic leg and physiotherapy, and has since resumed his studies. Today, he is fully mobile and is rebuilding his life.



Click here to read the full story or scan the QR code.



DELIVERING CARE

Since the inception of the Program in 1996, a total of **2.2+ billion** of factor and **12.2+ million mg of non-factor replacement therapy** have been donated worldwide.

Key Performance Indicators (KPIs)


Acute bleeds treated versus people with hemophilia (PWH) on prophylaxis since 2021



Note: The WFH Quality Management System (QMS) and Standard Operating Procedures (SOPs) ensure that the WFH Humanitarian Aid Program respects all good distribution practices (GDP) requirements.

34,747

Hemophilia A and B patients treated (cumulative) since 2021




3,973

People with hemophilia (PWH) on prophylaxis under 10 years of age (cumulative) since 2021



2,700*

Surgeries since 2021



*Note: surgeries went down in 2025 versus 2024, an indication that prophylaxis is keeping PWHs healthier and reducing the need for invasive procedures.

LEVERAGING TRAINING AND LOGISTICS TO MAKE SUSTAINABLE CARE POSSIBLE

Training, logistics and compliance support are key endeavours for the WFH Humanitarian Aid Program. These activities provide the education and guidance that countries need to develop their infrastructure to provide lasting support.

Training strategies

Supporting communities

The expansion of the WFH Humanitarian Aid Program has drastically changed how PWBDs are supported. In the past, care was focused almost exclusively on acute bleeds—often for emergency situations. Now, care has moved in a much more sustainable direction, and the Program has adapted its training accordingly. This has been made possible by the following:

- Significantly higher volumes of treatment product donations
- More consistent and dependable shipping of treatment product
- Longer shelf life for treatment products
- Option to request special potencies of treatment product

- Ability to provide training both virtually and in person
- Flexibility to offer scheduled and as-needed sessions

As a result of this positive evolution, training has increasingly shifted from emergency care to procedures that aim to improve the long-term quality of life of PWBDs, such as:

- Prophylaxis, especially for children under five years of age
- Surgery and other procedures for PWBDs
- Joint care
- Management of inhibitors, including non-factor replacement therapies, and immune tolerance induction (ITI)

Training KPIs

The WFH Humanitarian Aid Program trained nearly 400 healthcare professionals in 2026, with a greater number of participants taking advantage of virtual sessions. The training covered key topics such as non-factor therapies, extended half-life (EHL) treatment, and hemophilia diagnosis and management.

Evaluating that support

The Knowledge Attitude Practice (KAP) model helps the WFH Humanitarian Aid Program team evaluate the lasting impact of training. The model looks at the sharing of Knowledge, the Attitude of participants after training has been completed, and the change in Practice of applying the knowledge learned.

Before workshop **54%**

After workshop **87%**

Increase in knowledge on the principles, indications, and delivery of prophylaxis after attending the workshop:

- Self-assessment before workshop: 54%
- Self-assessment six months after the workshop: 87%

Before workshop **55%**

After workshop **87%**

Increase in confidence in their understanding of how to develop, initiate, and maintain prophylaxis for PWBDs after attending the workshop:

- Self-assessment before workshop: 55%
- Self-assessment six months after the workshop: 87%

After workshop **70%**

Increase motivation to make changes in their clinical practice, including:

- Laboratory diagnosis and monitoring for inhibitors
- Clinical troubleshooting for patients under prophylaxis

Case study: ultrasound synovectomy training program changing lives

Healthcare professionals in Africa were trained in workshops in 2024 on an ultrasound technique related to ultrasound-guided joint injections using the Joint Tissue Activity and Damage Exam (JADE) protocol. They are now bringing their learnings home to better support their local inherited bleeding disorders communities. One example of this is Zambia, where an ultrasound/synovectomy program is improving mobility and reducing pain for people with hemophilia with joint damage.

We would like to thank Sanofi, Sobi, Roche and CSL Behring for their support of the ultrasound synovectomy program.

Ultrasound synovectomy program brings hope to Zambia

In Zambia, an ultrasound/synovectomy program is improving mobility and reducing pain for people with hemophilia with joint damage. Mutimba Bernard Mpabalwani, MD, Trauma Surgeon, University Teaching Hospital, Lusaka, was trained in Kenya in 2024 through a workshop focused on ultrasound-guided joint injections using the JADE protocol. Using the knowledge he gained there, he is transforming the quality of life of PWBDs by eliminating pain and giving them back their mobility.

TRAINING CASE STUDY

Zambia

FACTOR DONATED IN 2025
3.3 million IUs

NON-FACTOR REPLACEMENT
THERAPY DONATED IN 2025
68,000 mgs

PATIENTS TREATED IN 2025
83




Click here to read
the full story or scan
the QR code.



Third Edition of Diagnosis of Hemophilia and Other Bleeding Disorders: A Laboratory Manual

TRAINING CASE STUDY

Lab manual



Click [here](#) or scan the QR code to read "Third Edition of Diagnosis of Hemophilia and Other Bleeding Disorders: A Laboratory Manual".

In 2025, the WFH released the third edition of the *Diagnosis of Hemophilia and Other Bleeding Disorders: A Laboratory Manual*. This updated edition serves as an essential resource for laboratory professionals, clinicians, and researchers involved in the diagnosis and management of bleeding disorders. The new edition expands on several topics and covers new ones, such as: new tools for assessing laboratory quality, monitoring new therapies for hemophilia, congenital and acquired functional inhibitors, VWD in resource-poor settings, antiphospholipid antibody syndrome, pediatric populations, and fibrinolytic disorders. These updates address the evolving landscape of hemostasis diagnostics, ensuring that laboratory practices align with current standards and technologies.

Logistics and compliance

Logistics KPIs

Getting donated factor and non-factor replacement therapy to where it needs to be quickly and efficiently is a key responsibility for the WFH Humanitarian Aid Program team. In 2025, we continued to develop creative solutions to limit the risk of potentially catastrophic interruptions in treatment product donations to key areas.

KPIs	2021	2022	2023	2024	2025
Shipments	318	269	347	276	298
Vials	633,453	422,400	773,131	535,582	549,060
Gross weight (tons)	113	82	139	160	167
Compliance assessments	20	21	23	22	26

BSI Connect Virtual Assessment solution

The BSI Connect Virtual Assessment solution is a tool which allows the WFH to optimize the distribution of donated treatment products, making it possible to more rapidly establish countries' capacity to receive, store and distribute donated products while respecting WFH Standard Operating Procedures. In 2025, 26 countries were evaluated using the software. The goal for 2026 is to assess 40 countries out of the total list of 80 countries currently in our donation plan. The WFH plans on evaluating countries every two years.



ADVOCATING FOR CARE

Video case studies

Along with other WFH global and local advocacy efforts, the WFH Humanitarian Aid Program works with NMOs to advocate with governments to recognize and support their inherited bleeding disorders communities. Ultimately, government buy-in is required for a country to be able to provide fully sustainable care. Here are three video series that demonstrate the work the WFH Humanitarian Aid Program is doing in Armenia, Kyrgyzstan, and Zambia to help make sustainable care possible in those countries in the future.

Armenia

FACTOR DONATED IN 2025
3.3 million IUs

NON-FACTOR REPLACEMENT THERAPY DONATED IN 2025
53,000 mgs

PATIENTS TREATED IN 2025
102

Multi-year collaboration transforms life for PWBDs in Armenia

Years of sustained partnership between the Armenian Society of Hemophilia and the WFH have transformed care for people with hemophilia in Armenia—dramatically improving quality of life and medical outcomes. Factor was in short supply in the country for decades, leaving PWBDs unable to safely pursue everyday activities. The dire situation changed drastically in 2018, when regular donations of clotting factor and comprehensive training for medical staff changed everything. The result: a transformation in care.



[Click here](#) or scan the QR code to watch the video for “Long-term collaboration transforms hemophilia care in Armenia”.



[Click here](#) or scan the QR code to watch the video for “Improved care brings hope to Armenian families living with hemophilia”.

Kyrgyzstan

FACTOR DONATED IN 2025
6.7 million IUs

PATIENTS TREATED IN 2025
450

Levels of care consistently improving in Kyrgyzstan thanks to treatment access

The WFH Humanitarian Aid Program has brought hope to Kyrgyzstan, where once the situation was dire. “[In the past] there was no cryoprecipitate, no fresh frozen plasma. Patients came into the hospital with terrible pain, and they had to just lay there and wait,” said Meeri Eralieva, MD, of the National Centre of Hematology in Bishkek. Now, the quality of life for patients has improved, joint replacement surgeries are being performed for the first time in the country, and many patients have transitioned to home therapy and prophylactic treatment. For PWBDs in the country, hopelessness has been replaced by a future of possibility.



[Click here](#) or scan the QR code to watch the video for “Access to treatment improves levels of care in Kyrgyzstan”.



[Click here](#) or scan the QR code to watch the video for “WFH brings new hope to people with hemophilia in Kyrgyzstan”.

Zambia

FACTOR DONATED IN 2025
3.3 million IUs

NON-FACTOR REPLACEMENT THERAPY DONATED IN 2025
68,000 mgs

PATIENTS TREATED IN 2025
83

From crisis to control: the effect of WFH support in Zambia


The WFH supports the inherited bleeding disorders community in Zambia through a range of initiatives designed to help the country build a health infrastructure that can deliver long-term, reliable care. Life-saving factor and non-factor replacement therapy donations provided by the WFH Humanitarian Aid Program are helping the local community to gain the credibility and confidence it needs to care for BWBDs in the country, and advocate with confidence with the government.



[Click here](#) or scan the QR code to watch the video for “Making a difference in Zambia, one patient at a time”.



[Click here](#) or scan the QR code to watch the video for “From crisis to control: the effect of WFH support in Zambia”.



Countries that collaborated with the WFH in 2025

80 countries received donations

Afghanistan	Egypt	Maldives	South Africa
Angola	El Salvador	Mali	South Sudan
Armenia	Eritrea	Mauritania	Sri Lanka
Bahamas	Ethiopia	Mauritius	Sudan
Bangladesh	Fiji	Mongolia	Suriname
Barbados	Gabon	Morocco	Syria
Belize	Gambia	Mozambique	Tajikistan
Benin	Ghana	Myanmar	Thailand
Bolivia	Guinea	Nauru	Tanzania
Botswana	Guyana	Nepal	Togo
Burkina Faso	Honduras	Nicaragua	Trinidad and Tobago
Burundi	India	Niger	Uganda
Cambodia	Indonesia	Nigeria	Ukraine
Cameroon	Jamaica	Pakistan	Uzbekistan
Congo	Jordan	Palestine	Venezuela
Côte d'Ivoire	Kenya	Paraguay	Thailand
Democratic Republic of the Congo (DRC)	Kosovo	Peru	Zambia
Djibouti	Kyrgyzstan	Philippines	Zimbabwe
Dominican Republic	Lebanon	Rwanda	
	Lesotho	Saint Lucia	
	Madagascar	Senegal	
	Malawi	Sierra Leone	

Note: most countries that received factor also received training.

WORKING TOGETHER TO SUPPORT TREATMENT FOR ALL

The WFH Humanitarian Aid Program improves the lack of access to care and treatment by providing much-needed support to people with inherited bleeding disorders in developing countries. By providing patients with a more predictable and sustainable flow of donations, the WFH Humanitarian Aid Program makes it possible for patients to receive consistent and reliable access to treatment and care.

None of this would be possible without the generous support of our sponsors.

Founding Visionary Contributors



“As a science-driven company, Sanofi’s commitment to innovation comes with a responsibility to increase access to care for people in need. Through our founding visionary partnership with the WFH Humanitarian Aid Program alongside Sobi, we’ve turned this responsibility into action, providing access to treatment to tens of thousands of people living with hemophilia in more than 50 countries. We remain honoured to continue this successful collaboration in which we can help provide not only access to treatment, but also the support and hope for the future that the global hemophilia community deserves.”

—Burcu Eryilmaz, Global Head of Rare Diseases **Sanofi**

“At Sobi, we remain committed to advancing sustainable hemophilia care beyond product donation alone. Our partnership with the WFH Humanitarian Aid Program supports not only access to treatment, but also the development of local expertise through medical education and care infrastructure to improve long term outcomes. We remain dedicated to advancing access to care around the world and are honoured to continue contributing to the Program as Founding Visionary Contributors with Sanofi.”

—Lydia Abad-Franch, MD, MBA, Head of Research, Development, and Medical Affairs (RDMA), and Chief Medical Officer, **Sobi**

Visionary Contributors



“At Bayer, we are guided by our vision of ‘Health for All, Hunger for None’. This is why we are very proud to work in close collaboration with the WFH Humanitarian Aid Program to provide support and access to treatment for people with hemophilia where it is needed most. As part of our long-standing commitment to the global hemophilia community, the strong alliance between the WFH and Bayer is both a testament and a great opportunity to make a life changing difference in people’s lives.”

—Martin Renze-Westendorf, Global Therapeutic Area Head for Hemophilia, **Bayer**



“We recognize the challenges and urgency of equitable access to life-saving treatments and care for people living with bleeding disorders worldwide. CSL is proud to be a longtime partner of the WFH Humanitarian Aid Program and supports its vital work in creating meaningful change, improved outcomes and lasting progress for individuals, communities and healthcare systems. We are driven by our common purpose of addressing unmet needs and ensuring sustainable access to treatment alongside effective education and advocacy. We look forward to strengthening our collaboration to advance standards of care, improving quality of life and delivering enduring impact for the bleeding disorders communities around the world.”

—Kate Priestman, Chief Corporate & External Affairs Officer, **CSL Behring**

Visionary Contributors



Genentech
A Member of the Roche Group



“At Roche, we believe that we are stronger together as a community. Creating more health equity and access to treatment and care for people living with bleeding disorders, globally, is an important goal for us. We are proud to support the WFH Humanitarian Aid Program

in its mission to help address the need for greater access to therapies, particularly in developing countries. Effective therapies can contribute to improving the quality of life of people with hemophilia A and their families. Listening to, and collaborating with, the hemophilia community in their efforts to improve the lives of people living with hemophilia A is a top priority for Roche. Improving the healthcare systems and working towards greater government engagement in all countries is important for creating sustainable access to therapies.”

—Daud Chaudry, Global Head of Hemophilia, **Roche**

Leadership Contributor

GRIFOLS

“The WFH Humanitarian Aid Program is a transformative force, bringing lifesaving treatment and hope to people with bleeding disorders who would otherwise go without care. Grifols is honoured to contribute sustainable product donations that help expand access to essential treatment in underserved communities. Through collaboration, compassion, and sustained support, the Program continues to change lives and build a healthier, more inclusive world.”

—Chris Healey, Senior Vice President, Corporate Affairs, **Grifols**

Contributor



“Takeda remains deeply committed to advancing global health equity through our long-standing partnership with the WFH Humanitarian Aid Program. The Program’s measurable impact, from providing essential therapies to strengthening diagnostic and clinical capabilities, truly shows the value of sustained collaboration. We are proud to contribute to these meaningful improvements for people with bleeding disorders around the world.”

—Giles Platford, President, Plasma-Derived Therapies Business Unit, **Takeda**

Other Partners

KUEHNE+NAGEL



“The WFH is a leading partner in the aid and relief sector.

Throughout the development

of our partnership, Kuehne + Nagel Inc has worked closely with the WFH to develop strategic shipping solutions. It is incredibly rewarding to see the successful delivery of shipments that reach patients with critical needs. We are truly grateful for our joint partnership with the WFH team, and are proud of the impact we are able to make together.”

—Rennie Johnson, Director, Humanitarian Aid & Relief; Anthony Catapano, Senior Director, Head Humanitarian Aid NAM, **Kuehne + Nagel Inc.**

odoo

“Supporting the WFH in its mission to deliver life-saving therapies worldwide is something we at Odoo are truly proud of. By helping WFH streamline logistics, enhance traceability, and improve operational efficiency, we are contributing to a world where treatments reach the patients who need them most”

—Julien Bertrand, VP of Marketing, **Odoo Inc.**

Hemophilia of Georgia



“Hemophilia of Georgia was started by families with the mission to support each other and create a future for all people impacted by bleeding disorders. More than 50 years later, we continue to honour this commitment by partnering with the World Federation of Hemophilia to bring hope, lessen the effects of bleeding disorders, and develop sustainable programs in low and middle-income countries. We know that by working hand-in-hand with our partners across the world, we can save lives, improve outcomes, and create a world where people with bleeding disorders thrive.”

—Deniece Chevannes, Vice President of Public Policy, Health Equity, and Research, **Hemophilia of Georgia**

PARTNERS RENEW COLLABORATION

with WFH Humanitarian Aid Program

Sanofi and Sobi extend partnership with the WFH Humanitarian Aid Program

In April 2025, the WFH and WFH USA, together with Sanofi, through its philanthropic organization Foundation S, and Sobi, announced the signing of a contract providing support to the WFH Humanitarian Aid Program in the form of medicine donations and financial assistance for up to five years.

The contract includes the donation of up to 100 million international units (IU) of factor therapy per year that will be distributed by the WFH Humanitarian Aid Program worldwide to developing countries. This will enable the WFH to deliver aid to people with inherited bleeding disorders across the globe. Between 2014 and 2025, Sanofi and Sobi have provided one billion IUs of treatment product, enabling the treatment of 22,219 people with inherited bleeding disorders (cumulative number).

“Building on the legacy of the original ten-year, one billion IU commitment, this new agreement reaffirms Sanofi and Sobi’s dedication to creating a predictable, sustainable program that addresses unmet needs and advances the standard of care for hemophilia worldwide. Over the past decade, these contributions have expanded treatment availability and transformed patient outcomes—and this renewal ensures that impact continues for years to come.”

—Alaa Hamed, Global Head of Medical Affairs, Rare Disease, **Sanofi**

“We are immensely proud to continue our contributions to the WFH Humanitarian Aid Program. Since the initial pledge, over 22,000 people with hemophilia have been treated with factor donated by Sobi and Sanofi. We are thrilled to continue our partnership with the WFH and look forward to the positive impact it will have on the lives of those affected by inherited bleeding disorders.”

—Lydia Abad-Franch, Head of R&D and Chief Medical Officer, **Sobi**



[Click here](#) or scan the QR code to read “Sanofi and Sobi extend partnership with the World Federation of Hemophilia Humanitarian Aid Program”.

Takeda and WFH Humanitarian Aid Program announce 5-year agreement renewal

In 2025, the WFH and WFH USA announced a renewed five-year agreement with Takeda, extending the company’s support for the WFH Humanitarian Aid Program from 2026 to 2030. Takeda will donate five million IUs of factor VIII with vWF and eight million IUs of aPCC annually, along with funding to cover handling and distribution. The agreement brings Takeda’s total donations to 215 million IUs up to 2030, supporting people with hemophilia, inhibitors and von Willebrand disease—especially women and girls.

“We are honoured to have contributed to improving the lives of thousands of patients for over a decade through this partnership, and we look forward to helping further bridge gaps in treatment access in underserved regions. We remain committed to our shared mission of ensuring equitable care and to our longstanding collaboration with the WFH.”

—Thomas R. Kreil, Vice President, Global Pathogen Safety, **Takeda**



[Click here](#) or scan the QR code to read “Takeda and WFH Humanitarian Aid Program announce renewed 5-year agreement”.

WFH Humanitarian Aid Program

KEY PERFORMANCE INDICATORS

KPIs	2021	2022	2023	2024	2025
Operational metrics					
Patients treated by donations (cumulative)	22,159	25,183	26,143	29,632	34,747
Total donations in MIUs	307	197	265	291	298
Total donations in mgs of non-factor replacement therapy	2,561,750	3,264,800	2,783,250	2,800,000	14,700,000
Number of countries receiving donations	74	72	78	76	80
Mean age of PWH* receiving treatment	21	21	20	22	22
Total number of infusions related to acute bleed treatment	159,458	63,492	116,067	141,494	183,722
Impact metrics					
Number of countries doing surgeries	26	22	32	31	28
New countries doing surgeries	2	2	8	3	N/A
Total number of surgeries	838	1,461	1,768	2,958	2,700
Life and limb-saving surgeries	83	72	83	167	38
Number of acute bleeds treated	62,349	41,771	30,598	37,907	43,951
Impact metrics (cumulative)					
Number of PWH on prophylaxis	2,836	3,964	6,429	6,591	7,294
PWH on prophylaxis under 10 years of age	1,251	1,540	3,102	3,351	3,937
Activity metrics					
Number of workshop attendees	1,468	470	385	435	453
Virtual	1,468	364	284	285	285
In-person	-	106	101	150	168

* PWH: person with hemophilia



YOUR CONTINUED SUPPORT HELPS US TO:

Increase quality of care

Increase the number of patients treated

Improve quality of life

Enhance diagnosis

Advocate for better care

For more information, please contact us at:

WORLD FEDERATION OF HEMOPHILIA

1184 rue Sainte-Catherine Ouest
Bureau 500, Montréal (Québec)
H3B 1K1 Canada
T +1 514.875.7944

humanitarianaid@wfh.org
wfh.org
treatmentforall.org



Charitable solicitations for the common purposes of WFH and WFH USA within the U.S. are conducted through WFH USA, a 501(c)3 affiliated entity.

Printed in Canada – Design: Lanla.com

Cover photo: HA visit – Kyrgyzstan – January 2025